LB Pharmaceuticals Sees Schizophrenia Drug Derivative As New Option For US Patients

With positive Phase II data for its amisulpride derivative, LB is planning a Phase III program to show safety and convenience with a lower dose that passes more easily through the blood-brain barrier.